The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2025 | Evaluating the efficacy of carboplatin plus pemetrexed in NSCLC
Igor Gómez-Randulfe, MBBS, The Christie NHS Foundation Trust, Manchester, UK, emphasizes the importance of escalation strategies in improving patient outcomes in advanced EGFR-mutant non-small cell lung cancer (NSCLC). Whilst various trials assessing treatment combinations incorporating carboplatin plus pemetrexed have shown success, not all patients will be fit for more aggressive approaches. This nuanced approach is crucial in optimizing treatment plans for patients in this setting. This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We now have results of several clinical trials comparing carboplatin and pemetrexed with carboplatin and pemetrexed plus another compound, another drug, and those phase three clinical trials with the ivosidenib, for instance, have shown positive results. So it is important to know that we have these escalation strategies to improve the outcomes of our patients, but we should also keep in mind that most of our patients will not be fit for those escalation strategies and therefore it is very important to sequence treatments appropriately...
We now have results of several clinical trials comparing carboplatin and pemetrexed with carboplatin and pemetrexed plus another compound, another drug, and those phase three clinical trials with the ivosidenib, for instance, have shown positive results. So it is important to know that we have these escalation strategies to improve the outcomes of our patients, but we should also keep in mind that most of our patients will not be fit for those escalation strategies and therefore it is very important to sequence treatments appropriately.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
